Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage: Re: Mares-Garcia E, Palazon-Bru A, Martinez-Martin A, et al. Non-guideline-recommended prescribing of proton pump inhibitors in the general population.

Brian Godman; Joseph Fadare

doi:10.1080/03007995.2017.1358159

Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage: Re: Mares-Garcia E, Palazon-Bru A, Martinez-Martin A, et al. Non-guideline-recommended prescribing of proton pump inhibitors in the general population.

Brian Godman^*, Joseph Fadare

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

1 Citation (Scopus)

Abstract

Drs Godman and Fadare review the paper by Mares-Garcia and colleagues in Spain regarding the extent of non-guideline recommended prescribing (NGRP) of proton pump inhibitors (PPIs) in ambulatory care. NGRP of PPIs is an increasing public health concern given the implications of overuse of PPIs on infection rates, osteoporosis and chronic kidney disease as well as increasing polypharmacy rates. Costs are less of an issue especially where there are low prices for generic PPIs; the main focus is on improving the quality of PPI prescribing. Encouragingly, Mares-Garcia and colleagues identified key factors associated with NGRP, providing direction to others.

Original language	English
Pages (from-to)	2085-2087
Number of pages	3
Journal	Current Medical Research and Opinion
Volume	33
Issue number	11
DOIs	https://doi.org/10.1080/03007995.2017.1358159
Publication status	Published - 2 Nov 2017
Externally published	Yes

Keywords

Guidelines
PPIs
prescribing
public health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/03007995.2017.1358159

Fingerprint

Dive into the research topics of 'Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage: Re: Mares-Garcia E, Palazon-Bru A, Martinez-Martin A, et al. Non-guideline-recommended prescribing of proton pump inhibitors in the general population.'. Together they form a unique fingerprint.

Cite this

Godman, B., & Fadare, J. (2017). Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage: Re: Mares-Garcia E, Palazon-Bru A, Martinez-Martin A, et al. Non-guideline-recommended prescribing of proton pump inhibitors in the general population. Current Medical Research and Opinion, 33(11), 2085-2087. https://doi.org/10.1080/03007995.2017.1358159

Godman, Brian ; Fadare, Joseph. / Non-guideline-recommended prescribing of proton pump inhibitors : implications for the future and reducing over usage: Re: Mares-Garcia E, Palazon-Bru A, Martinez-Martin A, et al. Non-guideline-recommended prescribing of proton pump inhibitors in the general population. In: Current Medical Research and Opinion. 2017 ; Vol. 33, No. 11. pp. 2085-2087.

@article{d6e103d3e7464f47a070e526d7a5a278,

title = "Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage: Re: Mares-Garcia E, Palazon-Bru A, Martinez-Martin A, et al. Non-guideline-recommended prescribing of proton pump inhibitors in the general population.",

abstract = "Drs Godman and Fadare review the paper by Mares-Garcia and colleagues in Spain regarding the extent of non-guideline recommended prescribing (NGRP) of proton pump inhibitors (PPIs) in ambulatory care. NGRP of PPIs is an increasing public health concern given the implications of overuse of PPIs on infection rates, osteoporosis and chronic kidney disease as well as increasing polypharmacy rates. Costs are less of an issue especially where there are low prices for generic PPIs; the main focus is on improving the quality of PPI prescribing. Encouragingly, Mares-Garcia and colleagues identified key factors associated with NGRP, providing direction to others.",

keywords = "Guidelines, PPIs, prescribing, public health",

author = "Brian Godman and Joseph Fadare",

note = "Publisher Copyright: {\textcopyright} 2017 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2017",

month = nov,

day = "2",

doi = "10.1080/03007995.2017.1358159",

language = "English",

volume = "33",

pages = "2085--2087",

journal = "Current Medical Research and Opinion",

issn = "0300-7995",

publisher = "Taylor and Francis Ltd.",

number = "11",

}

Godman, B & Fadare, J 2017, 'Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage: Re: Mares-Garcia E, Palazon-Bru A, Martinez-Martin A, et al. Non-guideline-recommended prescribing of proton pump inhibitors in the general population.', Current Medical Research and Opinion, vol. 33, no. 11, pp. 2085-2087. https://doi.org/10.1080/03007995.2017.1358159

Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage: Re: Mares-Garcia E, Palazon-Bru A, Martinez-Martin A, et al. Non-guideline-recommended prescribing of proton pump inhibitors in the general population. / Godman, Brian; Fadare, Joseph.
In: Current Medical Research and Opinion, Vol. 33, No. 11, 02.11.2017, p. 2085-2087.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Non-guideline-recommended prescribing of proton pump inhibitors

T2 - implications for the future and reducing over usage: Re: Mares-Garcia E, Palazon-Bru A, Martinez-Martin A, et al. Non-guideline-recommended prescribing of proton pump inhibitors in the general population.

AU - Godman, Brian

AU - Fadare, Joseph

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Drs Godman and Fadare review the paper by Mares-Garcia and colleagues in Spain regarding the extent of non-guideline recommended prescribing (NGRP) of proton pump inhibitors (PPIs) in ambulatory care. NGRP of PPIs is an increasing public health concern given the implications of overuse of PPIs on infection rates, osteoporosis and chronic kidney disease as well as increasing polypharmacy rates. Costs are less of an issue especially where there are low prices for generic PPIs; the main focus is on improving the quality of PPI prescribing. Encouragingly, Mares-Garcia and colleagues identified key factors associated with NGRP, providing direction to others.

AB - Drs Godman and Fadare review the paper by Mares-Garcia and colleagues in Spain regarding the extent of non-guideline recommended prescribing (NGRP) of proton pump inhibitors (PPIs) in ambulatory care. NGRP of PPIs is an increasing public health concern given the implications of overuse of PPIs on infection rates, osteoporosis and chronic kidney disease as well as increasing polypharmacy rates. Costs are less of an issue especially where there are low prices for generic PPIs; the main focus is on improving the quality of PPI prescribing. Encouragingly, Mares-Garcia and colleagues identified key factors associated with NGRP, providing direction to others.

KW - Guidelines

KW - PPIs

KW - prescribing

KW - public health

UR - http://www.scopus.com/inward/record.url?scp=85027520997&partnerID=8YFLogxK

U2 - 10.1080/03007995.2017.1358159

DO - 10.1080/03007995.2017.1358159

M3 - Comment/debate

C2 - 28724310

AN - SCOPUS:85027520997

SN - 0300-7995

VL - 33

SP - 2085

EP - 2087

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

IS - 11

ER -

Godman B, Fadare J. Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage: Re: Mares-Garcia E, Palazon-Bru A, Martinez-Martin A, et al. Non-guideline-recommended prescribing of proton pump inhibitors in the general population. Current Medical Research and Opinion. 2017 Nov 2;33(11):2085-2087. doi: 10.1080/03007995.2017.1358159